An upregulation of UCP2 has already been reported for several cancer types, including breast invasive cancer, thyroid carcinoma, lung carcinoma, bladder urothelial cancer, and colorectal adenocarcinoma (Madreiter-Sokolowski et al., 2017b). Here, UCP2 is linked to bladder transitional cell carcinoma.